Fate Therapeutics (FATE) Competitors

Nuvation Bio (NYSE:NUVB) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.

Is NUVB or FATE more profitable?

Nuvation Bio has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Nuvation Bio's return on equity of -21.89% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	N/A	-21.89%	-17.86%
Fate Therapeutics	-1,325.43%	-45.88%	-33.95%

Do analysts recommend NUVB or FATE?

Nuvation Bio presently has a consensus target price of $6.60, indicating a potential upside of 134.46%. Fate Therapeutics has a consensus target price of $6.75, indicating a potential upside of 259.04%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fate Therapeutics	0 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.30

Does the media prefer NUVB or FATE?

In the previous week, Fate Therapeutics had 2 more articles in the media than Nuvation Bio. MarketBeat recorded 4 mentions for Fate Therapeutics and 2 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.55 beat Fate Therapeutics' score of 0.25 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals have more ownership in NUVB or FATE?

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community favor NUVB or FATE?

Fate Therapeutics received 437 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 78.18% of users gave Nuvation Bio an outperform vote while only 68.09% of users gave Fate Therapeutics an outperform vote.

Company	Underperform	Outperform
Nuvation Bio	Outperform Votes 43 78.18%	Underperform Votes 12 21.82%
Fate Therapeutics	Outperform Votes 480 68.09%	Underperform Votes 225 31.91%

Which has more risk & volatility, NUVB or FATE?

Nuvation Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

Which has better valuation and earnings, NUVB or FATE?

Nuvation Bio has higher earnings, but lower revenue than Fate Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$2.16M	438.22	-$75.80M	-$2.17	-1.30
Fate Therapeutics	$13.45M	15.92	-$160.93M	-$1.65	-1.14

Summary

Nuvation Bio beats Fate Therapeutics on 10 of the 18 factors compared between the two stocks.